News Sentiment

ERNA sentiment intelligence

Eterna Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.42 Week of 17 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+5.9% over one week, +3.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Ernexa Therapeutics announces 1-for-25 reverse stock split; shares down

Market Reaction

Price moving ahead of tone

70/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 5.9% Price confirming higher
Trend fit Trend inactive 3.5% over four weeks
Fair value -98.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 32
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 7
TradingView 6
GlobeNewswire 5
Moomoo 4
Quiver Quantitative 3
MT Newswires 2
Benzinga 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 14
Regulatory and legal 4
Guidance 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
TradingView Direct company coverage

Price to book forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW

This article provides a brief mention of the "Price to book forward" for Ernexa Therapeutics Inc. (NASDAQ: ERNAW). It appears to be a financial data point from TradingView, indicating that the market for this stock is currently closed with no trades. The content is very minimal,

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 11:42
Source
TradingView
timothysykes.com Direct company coverage

ERNA Stock Draws Trader Attention As Biotech Maps 2026–2027 Trial Roadmap

Ernexa Therapeutics Inc. (ERNA) stock surged by 45.05% due to promising clinical trial developments for its ERNA-101 cell therapy. The company plans to file an IND for ERNA-101 in Q3 2026, begin a Phase 1 trial in Q4 2026 for platinum-resistant ovarian cancer, and expects initial

Tone
Positive 81/100
Event
Guidance
Published
15 Jul 2026 16:42
Source
timothysykes.com
Market source Direct company coverage

Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)

Ernexa Therapeutics (ERNA) shares soared 30% after an independent preclinical study validated its lead cell therapy candidate, ERNA-101, for ovarian cancer. The study, which replicated earlier findings, showed complete tumor clearance and extended survival in 67% of treated anima

Tone
Positive 90/100
Event
Market update
Published
15 Jul 2026 13:13
Source
Market source
Benzinga Direct company coverage

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

This article lists several healthcare stocks that are experiencing significant movement in Wednesday's pre-market session. It highlights both gainers, such as Ernexa Therapeutics and Catheter Precision, and losers, including Cardiff Oncology and NextCure, detailing their percenta

Tone
Positive 72/100
Event
Market update
Published
15 Jul 2026 12:13
Source
Benzinga
GlobeNewswire Direct company coverage

Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

Ernexa Therapeutics announced independent validation of its lead cell therapy candidate, ERNA-101, showing complete tumor clearance and durable survival in ovarian cancer models when combined with anti-PD-1 therapy. This preclinical data, which reproduced earlier findings in a la

Tone
Positive 72/100
Event
Market update
Published
15 Jul 2026 12:13
Source
GlobeNewswire
Market source Direct company coverage

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

Ernexa Therapeutics released a new "CEO Corner" featuring CEO Sanjeev Luther discussing the company's lead cell therapy candidate, ERNA-101, for advanced ovarian cancer. The video highlights ERNA-101's potential to transform immunologically "cold" tumors into those the immune sys

Tone
Positive 75/100
Event
Market update
Published
14 Jul 2026 13:17
Source
Market source
Stock Titan Direct company coverage

Preclinical ovarian models: Ernexa's ERNA-101 cleared tumors with PD-1 blockade

Ernexa Therapeutics released a CEO Corner video highlighting preclinical data for ERNA-101, its lead therapy candidate for platinum-resistant ovarian cancer. The video showcased complete tumor clearance and 100% long-term survival in ovarian cancer models when ERNA-101 was combin

Tone
Positive 71/100
Event
Market update
Published
14 Jul 2026 13:17
Source
Stock Titan
Stock Titan Direct company coverage

Updated July 2026 investor presentation from Ernexa Therapeutics (NASDAQ: ERNA)

Ernexa Therapeutics Inc. (NASDAQ: ERNA) has furnished an updated investor presentation for July 2026 as part of a current report on Form 8-K. This updated presentation, which refreshes materials from February 2026, is available as Exhibit 99.1 and on the company's investor relati

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:12
Source
Stock Titan
Stock Titan Direct company coverage

Ernexa Therapeutics (ERNA) investors back directors, auditor and 2026 equity plan

Ernexa Therapeutics Inc. (ERNA) shareholders approved the election of five directors, ratified Haskell & White LLP as the independent auditor for the 2026 fiscal year, and adopted the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan. These decisions were made at the 20

Tone
Positive 72/100
Event
Market update
Published
02 Jul 2026 20:12
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Ernexa Therapeutics Inc. – BOATS:ERNAW

The article discusses the price to sales forward metric for Ernexa Therapeutics Inc. (ERNAW). It appears to be a financial data page from TradingView, indicating that the market is closed and no trades have occurred for this specific metric.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 09:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Ernexa Therapeutics Inc. – BOATS:ERNAW

This article focuses on the "Price to earnings forward" metric for Ernexa Therapeutics Inc. (BOATS:ERNAW) as presented on TradingView. It appears to be a financial data snippet rather than a detailed analysis, indicating that there is no current trading activity or value for this

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 03:11
Source
TradingView
Stock Titan Direct company coverage

Ernexa Therapeutics (ERNA) finance SVP resigns, will aid transition

Ernexa Therapeutics Inc. announced the resignation of its Senior Vice President of Finance, Sandra Gurrola, effective July 3, 2026. Her resignation is not due to any disagreements with the company's operations or policies. Ms. Gurrola will provide part-time transition assistance

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 22:39
Source
Stock Titan
TradingView Direct company coverage

Sandra Gurrola to Resign as Ernexa's Senior VP of Finance, Effective July 3, 2026

Ernexa Therapeutics announced that Sandra Gurrola, Senior Vice President of Finance, will resign effective July 3, 2026. She will provide limited transition support and her departure is not due to disagreements with the company. Ernexa has initiated a search for her replacement.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:33
Source
TradingView
www.marketscreener.com Direct company coverage

Ernexa Therapeutics Inc. Announces Resignation of Sandra Gurrola from Senior Vice President of Finance, Effective July 3, 2026

Ernexa Therapeutics Inc. announced that Sandra Gurrola, Senior Vice President of Finance, has resigned, with her resignation becoming effective on July 3, 2026. Her departure is not due to any disagreements with the company. Ms. Gurrola will provide part-time transition assistanc

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 04:30
Source
www.marketscreener.com
Stock Titan Direct company coverage

Ernexa uses video to explain its cell-therapy strategy and patient mission

Ernexa Therapeutics has launched a "CEO Corner" video platform featuring CEO Sanjeev Luther to provide deeper insights into the company's progress, scientific strategy, and vision for cell therapies targeting advanced cancer and autoimmune diseases. The inaugural video outlines E

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 22:10
Source
Stock Titan
GlobeNewswire Direct company coverage

Ernexa Therapeutics Launches CEO Corner to Provide Deeper Accessibility

Ernexa Therapeutics has launched its new "CEO Corner" platform featuring CEO Sanjeev Luther. This initiative aims to provide stakeholders with deeper insights into the company's progress, scientific strategy, and vision for developing innovative, scalable, and affordable cell the

Tone
Positive 73/100
Event
Market update
Published
25 Jun 2026 13:42
Source
GlobeNewswire
Market source Direct company coverage

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

Ernexa Therapeutics is on track to become a clinical-stage biotechnology company with its lead oncology candidate, ERNA-101, slated for a Q3 2026 IND submission and a Q4 2026 first-in-human Phase 1 clinical study. The company has made significant progress in manufacturing and reg

Tone
Positive 72/100
Event
Market update
Published
19 Jun 2026 09:09
Source
Market source